| 000 | 01776 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250518062035.0 | ||
| 264 | 0 | _c20201030 | |
| 008 | 202010s 0 0 eng d | ||
| 022 | _a2045-2322 | ||
| 024 | 7 |
_a10.1038/s41598-019-50140-0 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aElango, Ramesh | |
| 245 | 0 | 0 |
_aConcurrent targeting of BMI1 and CDK4/6 abrogates tumor growth in vitro and in vivo. _h[electronic resource] |
| 260 |
_bScientific reports _c09 2019 |
||
| 300 |
_a13696 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 |
_aCell Cycle _xdrug effects |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Movement _xdrug effects |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 |
_aCyclin-Dependent Kinase 4 _xmetabolism |
| 650 | 0 | 4 |
_aCyclin-Dependent Kinase 6 _xmetabolism |
| 650 | 0 | 4 |
_aHeterocyclic Compounds, 2-Ring _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMitogen-Activated Protein Kinase 7 _xmetabolism |
| 650 | 0 | 4 |
_aPiperazines _xpharmacology |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aPyridines _xpharmacology |
| 650 | 0 | 4 |
_aThiazoles _xpharmacology |
| 700 | 1 | _aVishnubalaji, Radhakrishnan | |
| 700 | 1 | _aManikandan, Muthurangan | |
| 700 | 1 | _aBinhamdan, Sarah Ibrahim | |
| 700 | 1 | _aSiyal, Abdul-Aziz | |
| 700 | 1 | _aAlshawakir, Yasser A | |
| 700 | 1 | _aAlfayez, Musaad | |
| 700 | 1 | _aAldahmash, Abdullah | |
| 700 | 1 | _aAlajez, Nehad M | |
| 773 | 0 |
_tScientific reports _gvol. 9 _gno. 1 _gp. 13696 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/s41598-019-50140-0 _zAvailable from publisher's website |
| 999 |
_c30138972 _d30138972 |
||